Transcranial Duplex Scanning and Single Photon Emission Computer Tomography (SPECT) in Parkinsonian Syndromes

The recruitment status of this study is unknown because the information has not been verified recently.
Verified January 2009 by Maastricht University Medical Center.
Recruitment status was  Active, not recruiting
Sponsor:
Information provided by:
Maastricht University Medical Center
ClinicalTrials.gov Identifier:
NCT00368199
First received: August 22, 2006
Last updated: January 12, 2009
Last verified: January 2009
  Purpose

The purpose of the study is to determine the sensitivity and specificity of transcranial duplex scanning (TCD) and single photon emission computer tomography (SPECT) in patients suspected of having Idiopathic Parkinson Disease (PD) or Atypical Parkinson Syndromes (APS) with as golden standard the clinical diagnosis after 2-year follow-up.


Condition Phase
Parkinson's Disease
Parkinsonian Syndrome
Multiple System Atrophy
Supranuclear Palsy, Progressive
Essential Tremor
Vascular Parkinsonism
Drug Induced Parkinsonism
Phase 0

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Diagnostic Value Transcranial Duplex Scanning and Single Photon Emission Tomography in Patients Suspected of Having Idiopathic Parkinson Disease or Atypical Parkinson Syndromes

Resource links provided by NLM:


Further study details as provided by Maastricht University Medical Center:

Biospecimen Retention:   None Retained

no biocpsicmens


Estimated Enrollment: 250
Study Start Date: September 2006
Estimated Study Completion Date: September 2010
  Show Detailed Description

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population

250 Patients with unclear parkinsonism at the outpatient clinic

Criteria

Inclusion Criteria:

  • Patients with unclear parkinsonism at the outpatient clinic

Exclusion Criteria:

  • Known diagnosis at presentation
  • Life expectation of less than two years because of a non neurological disease
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00368199

Locations
Netherlands
Vlaar AMM, resident in neurology
Maastricht, PO box 5800, Netherlands, 6202 AZ
Sponsors and Collaborators
Maastricht University Medical Center
Investigators
Principal Investigator: Wim EJ Weber, MD PhD Maastricht University Medical Center
  More Information

Additional Information:
Publications:
Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: AMM Vlaar, University hospital Maastricht, department of neurology
ClinicalTrials.gov Identifier: NCT00368199     History of Changes
Other Study ID Numbers: 1-Vlaar
Study First Received: August 22, 2006
Last Updated: January 12, 2009
Health Authority: Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)

Keywords provided by Maastricht University Medical Center:
single photon emission computer tomography (SPECT)
transcranial sonography
transcranial duplex scanning
parkinson's disease
atypical parkinson syndromes
parkinsonism
parkinsonian
diagnostic
progressive supranuclear paralysis

Additional relevant MeSH terms:
Parkinson Disease
Multiple System Atrophy
Shy-Drager Syndrome
Supranuclear Palsy, Progressive
Tremor
Parkinsonian Disorders
Essential Tremor
Atrophy
Basal Ganglia Diseases
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Movement Disorders
Neurodegenerative Diseases
Primary Dysautonomias
Autonomic Nervous System Diseases
Hypotension
Vascular Diseases
Cardiovascular Diseases
Ophthalmoplegia
Ocular Motility Disorders
Cranial Nerve Diseases
Tauopathies
Paralysis
Neurologic Manifestations
Eye Diseases
Signs and Symptoms
Dyskinesias
Pathological Conditions, Anatomical

ClinicalTrials.gov processed this record on August 18, 2014